Literature DB >> 1435738

Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.

D G Rhodes1, R Newton, R Butler, L Herbette.   

Abstract

The interaction of salmeterol with model membranes has been studied with regard to equilibrium and kinetic behavior, including determination of the membrane-based partition coefficient, the rate of dissociation of salmeterol from membranes, and the rate of association. These data were obtained in various membrane preparations and under various conditions (e.g., temperature, cholesterol content). The compound is very lipophilic, compared with other beta 2 agonists such as salbutamol, and has a rapid association rate and a moderate dissociation rate. The equilibrium data support the assertion that the salmeterol action measured in perfused tissue involves an exo-site for nonspecific binding that may be identified with or related to the lipid bilayer. The kinetic data in unilamellar and multilamellar liposomes of synthetic lipids further suggest that the approach to the exo-site and the active site may involve components in the native system other than the lipid bilayer in which the beta 2 receptor is located. These additional components may explain the slow onset and the extraordinarily long duration of action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1435738

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 4.  On the mechanism of the persistent action of salmeterol: what is the current position?

Authors:  R A Coleman
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

5.  Interaction of the NMDA receptor noncompetitive antagonist MK-801 with model and native membranes.

Authors:  J Moring; L A Niego; L M Ganley; M W Trumbore; L G Herbette
Journal:  Biophys J       Date:  1994-12       Impact factor: 4.033

Review 6.  Clinical pharmacokinetics of salmeterol.

Authors:  Mario Cazzola; Renato Testi; Maria Gabriella Matera
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  The thermodynamics of the partitioning of ionizing molecules between aqueous buffers and phospholipid membranes.

Authors:  Rupert P Austin; Patrick Barton; Andrew M Davis; Roger E Fessey; Mark C Wenlock
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

8.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.

Authors:  J A Bennett; A E Tattersfield
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

9.  Characteristics of the binding of tacrine to acidic phospholipids.

Authors:  J Y Lehtonen; M Rytömaa; P K Kinnunen
Journal:  Biophys J       Date:  1996-05       Impact factor: 4.033

10.  Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.

Authors:  Luis E Gimenez; Faiza Baameur; Sharat J Vayttaden; Richard B Clark
Journal:  Mol Pharmacol       Date:  2015-03-17       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.